Popov Sergey Sergeevich, Anufrieva Elena Igorevna, Kryl'skii Evgenii Dmitrievich, Shulgin Konstantin Konstantinovich, Verevkin Aleksey Nikolaevich, Popova Tatyana Nikolaevna, Pashkov Aleksander Nikolaevich
Voronezh State Medical University named after N.N. Burdenko, Studencheskaya Street 10, 394036 Voronezh, Russia.
Voronezh State University, Universitetskaya sq. 1, 394018 Voronezh, Russia.
J Diabetes Metab Disord. 2021 May 10;20(1):709-717. doi: 10.1007/s40200-021-00802-6. eCollection 2021 Jun.
The diabetic nephropathy is associated with oxidative stress and increases in pigment epithelium-derived factor (PEDF) level in the patient's blood. For the first time, authors investigated the effect of methylethylpiridinol addition to the therapy on oxidative status and pigment epithelium-derived factor concentrations, and examined the relationship between these indicators and clinical markers of pathology development.
Study design: open label randomized controlled trial study. Authors assessed the effect of methylethylpiridinol addition to the therapy vs basic treatment on antioxidant and NADPH-generating enzymes activity, glutathione's concentration and free radical-induced oxidation's intensity using a spectrophotometric method and iron-induced biochemiluminescence. The pigment epithelium-derived factor concentration in the serum was measured by enzyme-linked immunosorbent assay.
Patients receiving combination therapy with methylethylpiridinol showed a more substantial increase in activity of glutathione peroxidase (Δ = 0.04 ± 0.11, p = 0.002), glutathione transferase (Δ = 0.12 ± 0.08, p < 0.001) and the concentration of reduced glutathione (Δ = 0.30 ± 0.17, p = 0.039). In addition, there was a significant decrease in PEDF level (Δ = -6.4 ± 5.4, p = 0.004). Correlation analysis showed a negative link between Δ postprandial glucose and Δ NADP-isocitrate dehydrogenase (-0.39, p = 0.033), Δ reduced glutathione and Δ postprandial glucose (-0.372, p = 0.043), Δ glutathione transferase and Δ PEDF (-0.37, p = 0.044).
The methylethylpiridinol addition to the therapy had a more potent stimulating effect on the patients' oxidative status in comparison with standard treatment, and reliably decreased pigment epithelium-derived factor level in patients' serum. The observed differences seem to be associated with the antioxidant activity of methylethylpiridinol which contributing to the mitigation of oxidative stress reducing at diabetes mellitus.
糖尿病肾病与氧化应激及患者血液中色素上皮衍生因子（PEDF）水平升高有关。作者首次研究了在治疗中添加甲基乙基吡啶醇对氧化状态和色素上皮衍生因子浓度的影响，并研究了这些指标与病理发展临床标志物之间的关系。
研究设计：开放标签随机对照试验研究。作者采用分光光度法和铁诱导生物发光法，评估了在治疗中添加甲基乙基吡啶醇与基础治疗相比，对抗氧化和生成NADPH的酶活性、谷胱甘肽浓度以及自由基诱导氧化强度的影响。通过酶联免疫吸附测定法测量血清中色素上皮衍生因子的浓度。
接受甲基乙基吡啶醇联合治疗的患者，谷胱甘肽过氧化物酶活性（Δ = 0.04 ± 0.11，p = 0.002）、谷胱甘肽转移酶活性（Δ = 0.12 ± 0.08，p < 0.001）以及还原型谷胱甘肽浓度（Δ = 0.30 ± 0.17，p = 0.039）有更显著的升高。此外，PEDF水平显著降低（Δ = -6.4 ± 5.4，p = 0.004）。相关性分析显示，餐后血糖变化量与NADP - 异柠檬酸脱氢酶变化量之间呈负相关（-0.39，p = 0.033）；还原型谷胱甘肽变化量与餐后血糖变化量之间呈负相关（-0.372，p = 0.043）；谷胱甘肽转移酶变化量与PEDF变化量之间呈负相关（-0.37，p = 0.044）。
与标准治疗相比，在治疗中添加甲基乙基吡啶醇对患者的氧化状态有更强的刺激作用，并可靠地降低了患者血清中色素上皮衍生因子的水平。观察到的差异似乎与甲基乙基吡啶醇的抗氧化活性有关，其有助于减轻糖尿病患者的氧化应激。
